<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id><journal-title-group><journal-title>Annals of Hematology</journal-title></journal-title-group><issn pub-type="ppub">0939-5555</issn><issn pub-type="epub">1432-0584</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24162333</article-id><article-id pub-id-type="pmc">3889634</article-id><article-id pub-id-type="publisher-id">1937</article-id><article-id pub-id-type="doi">10.1007/s00277-013-1937-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kalmanti</surname><given-names>Lida</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Saussele</surname><given-names>Susanne</given-names></name><address><phone>+49-621-3836966</phone><fax>+49-621-3836969</fax><email>susanne.saussele@medma.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lauseker</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Proetel</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Martin C.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hanfstein</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schreiber</surname><given-names>Annette</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Fabarius</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Pfirrmann</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Schnittger</surname><given-names>Susanne</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Dengler</surname><given-names>Jolanta</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Falge</surname><given-names>Christiane</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Kanz</surname><given-names>Lothar</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Neubauer</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Stegelmann</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Pfreundschuh</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Waller</surname><given-names>Cornelius F.</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Spiekermann</surname><given-names>Karsten</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Krause</surname><given-names>Stefan W.</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Heim</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Nerl</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Hossfeld</surname><given-names>Dieter K.</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Kolb</surname><given-names>Hans-Jochem</given-names></name><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Hochhaus</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Hasford</surname><given-names>Joerg</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hehlmann</surname><given-names>R&#x000fc;diger</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><collab>German Chronic Myeloid Leukemia Study Group</collab></contrib><contrib contrib-type="author"><collab>Schweizerische Arbeitsgemeinschaft f&#x000fc;r Klinische Krebsforschung (SAKK)</collab></contrib><aff id="Aff1"><label/>III. Medizinische Klinik, Universit&#x000e4;tsmedizin Mannheim, Pettenkoferstrasse 22, 68169 Mannheim, Germany </aff><aff id="Aff2"><label/>Institut f&#x000fc;r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit&#x000e4;t M&#x000fc;nchen, Munich, Germany </aff><aff id="Aff3"><label/>MLL-M&#x000fc;nchner Leuk&#x000e4;mielabor GmbH, Munich, Germany </aff><aff id="Aff4"><label/>Abteilung Innere Medizin V, Medizinische Klinik, Universit&#x000e4;tsklinikum Heidelberg, Heidelberg, Germany </aff><aff id="Aff5"><label/>Medizinische Klinik 5, Klinikum N&#x000fc;rnberg Nord, N&#x000fc;rnberg, Germany </aff><aff id="Aff6"><label/>Medizinische Klinik, Abteilung II, Universit&#x000e4;tsklinikum T&#x000fc;bingen, T&#x000fc;bingen, Germany </aff><aff id="Aff7"><label/>Klinik f&#x000fc;r Innere Medizin, Schwerpunkt H&#x000e4;matologie, Onkologie und Immunologie, Universit&#x000e4;tsklinikum Marburg, Marburg, Germany </aff><aff id="Aff8"><label/>Klinik f&#x000fc;r Innere Medizin III, Universit&#x000e4;tsklinikum Ulm, Ulm, Germany </aff><aff id="Aff9"><label/>Klinik f&#x000fc;r Innere Medizin I, Universit&#x000e4;tsklinikum des Saarlandes, Homburg/Saar, Germany </aff><aff id="Aff10"><label/>Klinik f&#x000fc;r Innere Medizin I, Universit&#x000e4;tsklinikum Freiburg, Freiburg, Germany </aff><aff id="Aff11"><label/>Medizinische Klinik und Poliklinik III, Klinikum der Ludwig Maximilians-Universit&#x000e4;t, Munich, Germany </aff><aff id="Aff12"><label/>Medizinische Klinik 5, Universit&#x000e4;tsklinikum Erlangen, Erlangen, Germany </aff><aff id="Aff13"><label/>Klinik f&#x000fc;r H&#x000e4;matologie, Universit&#x000e4;tsspital, Basel, Switzerland </aff><aff id="Aff14"><label/>Klinik f&#x000fc;r H&#x000e4;matologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinik Schwabing, Munich, Germany </aff><aff id="Aff15"><label/>II. Medizinische Klinik, Universit&#x000e4;tsklinikum Eppendorf, Hamburg, Germany </aff><aff id="Aff16"><label/>Klinikum rechts der Isar, Technische Universit&#x000e4;t M&#x000fc;nchen, Munich, Germany </aff><aff id="Aff17"><label/>Abteilung H&#x000e4;matologie/Onkologie, Universit&#x000e4;tsklinikum Jena, Jena, Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>10</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>10</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>93</volume><issue>1</issue><fpage>71</fpage><lpage>80</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>9</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><p>Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed patients from the randomized CML study IV to investigate disease manifestations and outcome in different age groups. One thousand five hundred twenty-four patients with BCR-ABL-positive chronic phase CML were divided into four age groups: (1) 16&#x02013;29&#x000a0;years, <italic>n</italic>&#x02009;=&#x02009;120; (2) 30&#x02013;44&#x000a0;years, <italic>n</italic>&#x02009;=&#x02009;383; (3) 45&#x02013;59&#x000a0;years, <italic>n</italic>&#x02009;=&#x02009;495; and (4)&#x02009;&#x02265;60&#x000a0;years, <italic>n</italic>&#x02009;=&#x02009;526. Group 1 (adolescents and young adults (AYAs)) presented with more aggressive disease features (larger spleen size, more frequent symptoms of organomegaly, higher white blood count, higher percentage of peripheral blasts and lower hemoglobin levels) than the other age groups. In addition, a higher rate of patients with BCR-ABL transcript levels &#x0003e;10&#x000a0;% on the international scale (IS) at 3&#x000a0;months was observed. After a median observation time of 67.5&#x000a0;months, no inferior survival and no differences in cytogenetic and molecular remissions or progression rates were observed. We conclude that AYAs show more aggressive features and poor prognostic indicators possibly indicating differences in disease biology. This, however, does not affect outcome.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00277-013-1937-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic myeloid leukemia</kwd><kwd>Accelerated phase</kwd><kwd>Blast crisis</kwd><kwd>Young adults and adolescents</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Chronic myeloid leukemia (CML) appears in all age groups. The incidence increases with age. In western countries, median age at diagnosis is 64&#x000a0;years [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] and around 54&#x000a0;years [<xref ref-type="bibr" rid="CR3">3</xref>] in clinical studies. Before the introduction of imatinib, older age was a negative prognostic factor, as reflected by the risk stratification scores, Sokal and Euro [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. After the introduction of imatinib, the outcome of patients with CML has improved, and older age seems to have lost its negative impact [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p>A recent analysis that compares patients less than 65&#x000a0;years with patients older than 65&#x000a0;years treated with frontline imatinib reports no difference in an outcome between these two age groups [<xref ref-type="bibr" rid="CR8">8</xref>]. Another analysis that compares 15&#x02013;29-year-old adolescents and young adults (AYAs) with patients older than 29&#x000a0;years with newly diagnosed chronic phase (CP) CML treated with first-line tyrosine kinase inhibitors (TKIs) reports inferior response rates in the younger group [<xref ref-type="bibr" rid="CR9">9</xref>]. AYAs have been of particular interest in oncology because differences compared to older age have been observed in various neoplasias: In acute lymphoblastic leukemia, different disease features and a better outcome are reported in AYAs in comparison to older patients [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. A worse prognosis has been reported in breast cancer [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], colorectal cancer [<xref ref-type="bibr" rid="CR14">14</xref>], and soft tissue sarcomas [<xref ref-type="bibr" rid="CR15">15</xref>], pointing to different biological features of these cancers in younger age [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Few data exist on presentation and outcome of AYAs with CML possibly due to the low incidence of CML in this age group.</p><p>The aim of this study was to analyze the impact of age on outcome of CML using patients from the German CML study IV with particular attention to the group of patients younger than 29&#x000a0;years.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Patients and methods</title><p>The German CML study IV is a five-arm randomized study which compares 400&#x000a0;mg imatinib, 800&#x000a0;mg imatinib, 400&#x000a0;mg imatinib in combination with interferon alpha (IFN-&#x003b1;), 400&#x000a0;mg imatinib in combination with low-dose cytarabine, and 400&#x000a0;mg imatinib after failure to IFN-&#x003b1; [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Newly diagnosed BCR-ABL-positive CP-CML patients diagnosed in participating centers were included. There was no upper age limit. Patients with comorbidities that would preclude study participation or study drug treatment were excluded as well as pregnant or nursing women and patients with secondary malignancy causing reduced life expectancy or requiring therapy.</p><p>Patients, 16&#x000a0;years and older, were included. Twenty-nine years was defined as upper cutoff age for AYAs [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. For older patients, the lower cut off at age 60&#x000a0;years was chosen [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Age groups, 30&#x02013;59, were evenly divided into two groups (30&#x02013;44 and 45&#x02013;59).</p><p>Gender, performance status, risk scores, clinical manifestations, blood count, type of transcripts, and presence of additional chromosomal aberrations (ACAs) [<xref ref-type="bibr" rid="CR23">23</xref>] were analyzed at the time of diagnosis. Cytogenetic and molecular responses, rates of progression to accelerated phase (AP) and blast crisis (BC), and overall survival (OS) were analyzed throughout the observation time of the study. Patients were analyzed for achieving complete cytogenetic remission (CCR), major molecular remission (MMR), and molecular remission &#x02264;0.01&#x000a0;% on the international scale (MR<sup>4</sup>), if at least one sample of sufficient quality was available.</p><p>For follow-up analyses of CCR, at least 20 marrow cell metaphases were evaluated. Measurements of BCR-ABL and total ABL transcripts were determined by quantitative reverse transcriptase polymerase chain reactions from peripheral blood samples [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>] and were performed in standardized laboratories [<xref ref-type="bibr" rid="CR27">27</xref>]. The analysis of molecular endpoints was restricted to patients expressing b2a2 and/or b3a2 transcripts only.</p><p>Response definitions, AP, and BC were defined according to ELN criteria and the recent standardized definitions of molecular response [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. All living patients were censored at the time of their last visit. In estimating the cumulative incidences of molecular or cytogenetic remissions, patients were censored at the time they received a second-generation TKI or were transplanted.</p><p>OS was calculated from date of diagnosis to death from any cause (whether on or off TKI) or to the latest follow-up date.</p><p>Baseline characteristics and hematological parameters were compared with the chi-squared or the Kruskal&#x02013;Wallis tests. Cumulative incidences were calculated under consideration of competing risks [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] defined by AP, BC, and death. Probabilities of OS were calculated by the Kaplan&#x02013;Meier method and compared by log-rank test. Comparisons between cumulative incidences were performed by the Gray test [<xref ref-type="bibr" rid="CR33">33</xref>]. Relative overall survival was calculated dividing the observed survival probabilities by the expected survival probability of the general German population matching age and sex. Level of significance was 0.05. Due to the exploratory character of this work, no adjustment of <italic>p</italic> values was done. All calculations were performed with the SAS software Version 9.1.3.</p><p>The protocol followed the Declaration of Helsinki and was approved by the ethics committee of the Medizinische Fakult&#x000e4;t Mannheim der Universit&#x000e4;t Heidelberg and by local ethics committees of participating centers. Written informed consent was obtained from all patients before they entered the study.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p>One thousand five hundred fifty-one patients with newly diagnosed BCR-ABL-positive CML in CP were randomized from July 2002 through March 2012. Data entry was closed on May 24, 2012.</p><p>One thousand five hundred twenty-four patients at the age of 16&#x000a0;years and older were evaluable for follow-up (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The median age at diagnosis was 52&#x000a0;years. The median observation time was 67.5 (0.1&#x02013;123.8)&#x02009;months.<fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of evaluable patients according to age groups. <italic>n</italic> Number of patients, <italic>CML</italic> chronic myeloid leukemia, <italic>CP</italic> chronic phase, <italic>OS</italic> overall survival, <italic>CCR</italic> complete cytogenetic remission, <italic>MMR</italic> major molecular remission, <italic>MR</italic>
<sup><italic>4</italic></sup> molecular remission &#x02264;0.01&#x000a0;% on the international scale</p></caption><graphic xlink:href="277_2013_1937_Fig1_HTML" id="MO1"/></fig></p><p>Patients were divided into four age groups according to age at diagnosis: group 1, 16&#x02013;29&#x000a0;years (<italic>n</italic>&#x02009;=&#x02009;120, 8&#x000a0;%); group 2, 30&#x02013;44&#x000a0;years (<italic>n</italic>&#x02009;=&#x02009;383, 25&#x000a0;%); group 3, 45&#x02013;59&#x000a0;years (<italic>n</italic>&#x02009;=&#x02009;495, 32&#x000a0;%); and group 4, &#x02265;60&#x000a0;years (<italic>n</italic>&#x02009;=&#x02009;526, 35&#x000a0;%). All patients received imatinib as first or second-line treatment in the study except for ten patients who only received IFN. Recruitment to this arm was terminated in 2005 [<xref ref-type="bibr" rid="CR17">17</xref>]. More patients in group 1 were transplanted (19&#x000a0;%) compared to 12, 7, and 1&#x000a0;% in groups 2, 3, and 4, respectively. The number of patients according to age groups and therapy arm are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patients and treatment arms</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age groups, years</th><th>16&#x02013;29</th><th>30&#x02013;44</th><th>45&#x02013;59</th><th>At least 60</th></tr></thead><tbody><tr><td>All patients, <italic>n</italic>
</td><td char="." align="char">120</td><td char="." align="char">383</td><td char="." align="char">495</td><td char="." align="char">526</td></tr><tr><td>&#x02003;Imatinib (400&#x000a0;mg), <italic>n</italic> (%)</td><td char="(" align="char">25 (21)</td><td char="(" align="char">93 (24)</td><td char="(" align="char">131 (26)</td><td char="(" align="char">147 (28)</td></tr><tr><td>&#x02003;Imatinib (400&#x000a0;mg + IFN-&#x003b1;), <italic>n</italic> (%)</td><td char="(" align="char">39 (32)</td><td char="(" align="char">102 (27)</td><td char="(" align="char">139 (28)</td><td char="(" align="char">145 (27)</td></tr><tr><td>&#x02003;Imatinib (400&#x000a0;mg + cytarabine), <italic>n</italic> (%)</td><td char="(" align="char">13 (11)</td><td char="(" align="char">39 (10)</td><td char="(" align="char">53 (11)</td><td char="(" align="char">53 (10)</td></tr><tr><td>&#x02003;Imatinib (400&#x000a0;mg after IFN-&#x003b1; failure), <italic>n</italic> (%)</td><td char="(" align="char">8 (7)</td><td char="(" align="char">35 (9)</td><td char="(" align="char">37 (7)</td><td char="(" align="char">48 (9)</td></tr><tr><td>&#x02003;Imatinib (800&#x000a0;mg), <italic>n</italic> (%)</td><td char="(" align="char">35 (29)</td><td char="(" align="char">114 (29)</td><td char="(" align="char">135 (27)</td><td char="(" align="char">133 (25)</td></tr></tbody></table><table-wrap-foot><p>
<italic>N</italic> number of patients, <italic>IFN-&#x003b1;</italic> interferon</p></table-wrap-foot></table-wrap></p><p>There was a predominance of male gender in all age groups, but group 1 showed a significantly higher percentage of male patients in comparison to group 4 (67&#x000a0;% for groups 1 and 2 each, 61&#x000a0;% for group 3, and 54&#x000a0;% for group 4, <italic>p</italic>&#x02009;=&#x02009;0.011).</p><p>Most patients had a Karnofsky index &#x0003e;80&#x000a0;%, but 12&#x000a0;% of patients in group 1 had a Karnofsky index between 50&#x02013;80&#x000a0;% compared to 9&#x000a0;% in groups 2 and 3 and 16&#x000a0;% in group 4 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patient's characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age groups, years</th><th>16&#x02013;29</th><th>30&#x02013;44</th><th>45&#x02013;59</th><th>At least 60</th></tr></thead><tbody><tr><td>Number of patients, <italic>n</italic> (%)</td><td>120 (8)</td><td>383 (25)</td><td>495 (32)</td><td>526 (35)</td></tr><tr><td>&#x02003;Male</td><td>80 (67)</td><td>255 (67)</td><td>301 (61)</td><td>283 (54)</td></tr><tr><td>&#x02003;Female</td><td>40 (33)</td><td>128 (33)</td><td>194 (39)</td><td>243 (46)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td/><td/><td>0.011<sup>a</sup>
</td></tr><tr><td colspan="5">Karnofsky index, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;50&#x02013;80</td><td>13 (12)</td><td>31 (9)</td><td>42 (9)</td><td>74 (16)</td></tr><tr><td>&#x02003;&#x0003e;80&#x02013;&#x0003c;100</td><td>32 (29)</td><td>86 (25)</td><td>144 (32)</td><td>166 (35)</td></tr><tr><td>&#x02003;100</td><td>65 (59)</td><td>226 (66)</td><td>271 (59)</td><td>234 (49)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td>&#x0003c;0.001<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing</td><td>10</td><td>40</td><td>38</td><td>52</td></tr><tr><td colspan="5">EUTOS score, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;Low</td><td>97 (82)</td><td>320 (84)</td><td>436 (89)</td><td>473 (92)</td></tr><tr><td>&#x02003;High</td><td>22 (18)</td><td>63 (16)</td><td>54 (11)</td><td>41 (8)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td/><td>0.031<sup>a</sup>
</td><td>0.002<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing</td><td>1</td><td>0</td><td>5</td><td>12</td></tr><tr><td colspan="5">Sokal score <sup>b</sup>, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;Low</td><td>64 (54)</td><td>190 (50)</td><td>226 (46)</td><td>90 (17)</td></tr><tr><td>&#x02003;Intermediate</td><td>23 (19)</td><td>100 (26)</td><td>155 (32)</td><td>300 (58)</td></tr><tr><td>&#x02003;High</td><td>31 (26)</td><td>92 (24)</td><td>110 (22)</td><td>125 (24)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td/><td>0.035<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing</td><td>2</td><td>1</td><td>4</td><td>11</td></tr><tr><td colspan="5">Euro score <sup>b</sup>, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;Low</td><td>70 (59)</td><td>267 (70)</td><td>144 (29)</td><td>69 (13)</td></tr><tr><td>&#x02003;Intermediate</td><td>29 (24)</td><td>84 (22)</td><td>286 (58)</td><td>391 (75)</td></tr><tr><td>&#x02003;High</td><td>20 (17)</td><td>31 (8)</td><td>65 (13)</td><td>61 (12)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td>0.013<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing</td><td>1</td><td>1</td><td>0</td><td>5</td></tr><tr><td>Presence of organomegaly-related symptoms, <italic>n</italic> (%)</td><td>33 (29)</td><td>86 (24)</td><td>84 (18)</td><td>37 (7)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td/><td>0.009<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing</td><td>5</td><td>19</td><td>18</td><td>23</td></tr><tr><td>Spleen size, below costal margin</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Median (range), cm</td><td>5 (0&#x02013;38)</td><td>3 (0&#x02013;28)</td><td>1 (0&#x02013;25)</td><td>0 (0&#x02013;23)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td>0.014<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>1</td><td>0</td><td>2</td><td>6</td></tr><tr><td>Blasts in blood</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Median (range), %</td><td>2 (0&#x02013;19)<sup>c</sup>
</td><td>1 (0&#x02013;17)<sup>c</sup>
</td><td>1 (0&#x02013;30)<sup>c</sup>
</td><td>0 (0&#x02013;15)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td/><td>0.010<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>1</td><td>1</td><td>4</td><td>6</td></tr><tr><td>WBC</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Median (range), 10<sup>9</sup>/L</td><td>144 (9&#x02013;571)</td><td>106 (3&#x02013;539)</td><td>74 (3&#x02013;630)</td><td>57 (3&#x02013;582)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td>0.044<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>1</td><td>2</td><td>2</td><td>3</td></tr><tr><td colspan="5">Hemoglobin</td></tr><tr><td>&#x02003;Median (range), g/dL</td><td>11.1 (6.9&#x02013;16.2)</td><td>11.8 (5.2&#x02013;17.5)</td><td>12.6 (4.9&#x02013;19.1)</td><td>12.5 (4.7&#x02013;17.6)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td>0.041<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td><td>&#x0003c;0.001<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>2</td><td>3</td><td>3</td><td>5</td></tr><tr><td colspan="5">Eosinophils</td></tr><tr><td>&#x02003;Median (range), (%)</td><td>2.5 (0&#x02013;12)</td><td>2 (0&#x02013;13)</td><td>2 (0&#x02013;14)</td><td>2 (0&#x02013;28)</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>0</td><td>2</td><td>4</td><td>3</td></tr><tr><td colspan="5">Basophils</td></tr><tr><td>&#x02003;Median (range), (%)</td><td>3 (0&#x02013;19)</td><td>3 (0&#x02013;22)</td><td>4 (0&#x02013;26)</td><td>3 (0&#x02013;66)</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>0</td><td>2</td><td>5</td><td>6</td></tr><tr><td colspan="5">Platelets</td></tr><tr><td>&#x02003;Median (range), &#x000d7; 10<sup>9</sup>/L</td><td>430 (59&#x02013;2,590)</td><td>369 (39&#x02013;2,799)</td><td>364 (49&#x02013;3,020)</td><td>381 (34&#x02013;2,716)</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>0</td><td>1</td><td>1</td><td>2</td></tr><tr><td colspan="5">BCR-ABL transcript type, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;b2a2</td><td>55 (48)</td><td>146 (39)</td><td>200 (42)</td><td>186 (38)</td></tr><tr><td>&#x02003;b3a2</td><td>42 (36)</td><td>166 (45)</td><td>210 (44)</td><td>233 (47)</td></tr><tr><td>&#x02003;Either</td><td>18 (16)</td><td>61 (16)</td><td>65 (14)</td><td>72 (15)</td></tr><tr><td>&#x02003;Missing</td><td>5</td><td>10</td><td>20</td><td>35</td></tr><tr><td>ACAs, <italic>n</italic> (%)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Yes</td><td>6 (6)</td><td>13( 4)</td><td>22(5)</td><td>12(3)</td></tr><tr><td>&#x02003;No</td><td>98 (94)</td><td>321 (96)</td><td>421 (95)</td><td>452 (97)</td></tr><tr><td>&#x02003;Missing</td><td>16</td><td>49</td><td>52</td><td>62</td></tr><tr><td colspan="5">&#x0003e;10&#x000a0;% BCR-ABL <sup>IS</sup> at 3&#x000a0;months</td></tr><tr><td>&#x02003;
<italic>n</italic>, (%)</td><td>25(42)</td><td>74(42)</td><td>60 (26)</td><td>53 (25)</td></tr><tr><td>&#x02003;
<italic>p</italic>
</td><td/><td/><td>0.026<sup>a</sup>
</td><td>0.018<sup>a</sup>
</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>60</td><td>204</td><td>263</td><td>313</td></tr><tr><td colspan="5">&#x0003e;10&#x000a0;% BCR-ABL <sup>IS</sup> at 6&#x000a0;months</td></tr><tr><td>&#x02003;
<italic>n</italic>, (%)</td><td>6 (13)</td><td>30(19)</td><td>28(13)</td><td>29(15)</td></tr><tr><td>&#x02003;Missing, <italic>n</italic>
</td><td>72</td><td>224</td><td>272</td><td>320</td></tr></tbody></table><table-wrap-foot><p>BCR-ABL <sup>IS</sup> BCR-ABL transcript levels on international scale ACAs: additional cytogenetic aberrations except &#x02212;Y</p><p>
<sup>a</sup>
<italic>p</italic> value refers to test between group 1 and the respective groups. Values not shown were above 0.05</p><p>
<sup>b</sup>In Sokal and Euro score age is included for risk stratification</p><p>
<sup>c</sup>Eight patients with blasts in blood &#x0003e; 15&#x000a0;% were included as chronic phase patients after judged so by the treating physicians. All had bone marrow blasts &#x02264;10&#x000a0;%</p></table-wrap-foot></table-wrap></p><p>Patients in group 1 had the highest proportion of high-risk patients according to Euro and EUTOS scores. By EUTOS score, 18&#x000a0;% of patients in group 1 were high risk in comparison to 16&#x000a0;% (ns), 11&#x000a0;% (<italic>p</italic>&#x02009;=&#x02009;0.031), and 8&#x000a0;% (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.002) in groups 2, 3, and 4, respectively.</p><p>Group 1 presented with a larger spleen size (median length of 5&#x000a0;cm below the costal margin), more often with symptoms of organomegaly, higher white blood cell counts (WBC), a higher percentage of blasts in the peripheral blood (median of 144&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L), and lower hemoglobin levels (median of 11.1 g/dL). There were no differences in fatigue, weight loss, fever, or other symptoms, in the percentage of eosinophils, basophils, platelets, bone marrow blasts, ACAs, and type of BCR-ABL transcripts at diagnosis between the four groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p>No significant differences in cumulative incidences of CCR, MMR, and MR<sup>4</sup> were found between group 1 and the other 3 groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a&#x02013;c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>
<bold>a</bold>&#x02013;<bold>c</bold> Cumulative incidences of <bold>a</bold> CCR, <bold>b</bold> MMR, and <bold>c</bold> MR<sup>4</sup> according to the four age groups determined under consideration of competing risks. <italic>n</italic> Number of patients, <italic>CCR</italic> complete cytogenetic, remission, <italic>MMR</italic> major molecular remission, <italic>MR</italic>
<sup><italic>4</italic></sup> molecular remission &#x02264;0.01&#x000a0;% on the international scale. <italic>p</italic> refers to level of significance between AYAs and the other three age groups</p></caption><graphic xlink:href="277_2013_1937_Fig2_HTML" id="MO2"/></fig></p><p>The 5-year OS probability of group 1 was 96.7&#x000a0;%, 93.8&#x000a0;% for group 2, 92.5&#x000a0;% for group 3, and 82.9&#x000a0;% for group 4. OS was lower only in group 4 in comparison to the other three age groups (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) as observed in the general population [<xref ref-type="bibr" rid="CR34">34</xref>]. The relative survival (RS) when the general German population was taken into account was 96.9&#x000a0;% in group 1, 94.5, 95.1, and 93.1&#x000a0;% in groups 2&#x02013;4, respectively [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Regarding progression during the observation time, no differences were observed between the age groups. The cumulative incidences of progression at 5&#x000a0;years were 8.7, 7.3, 5.3, and 6.1&#x000a0;% for groups 1 to 4, respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Rates of progression to AP and BC according to age group. No statistical difference was observed between the four age groups. <italic>n</italic> Number of patients, <italic>AP</italic> accelerated phase, <italic>BC</italic> blast crisis, <italic>CI</italic> cumulative incidence. <italic>p</italic> refers to level of significance between AYAs and the other three age groups</p></caption><graphic xlink:href="277_2013_1937_Fig3_HTML" id="MO3"/></fig></p><p>More patients in group 1 had BCR-ABL <sup>IS</sup> &#x02265;10&#x000a0;% at 3&#x000a0;months (42&#x000a0;%) than patients above 44&#x000a0;years (26&#x000a0;% for group 3, <italic>p</italic>&#x02009;=&#x02009;0.026 and 25&#x000a0;% for group 4, <italic>p</italic>&#x02009;=&#x02009;0.018). There was no difference to group 2 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p>A correlation between a specific cause of death age group and therapy arm was not observed. Causes of death in each group are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Causes of death</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Age groups, years</th><th>16&#x02013;29</th><th>30&#x02013;44</th><th>45&#x02013;59</th><th>At least 60</th></tr></thead><tbody><tr><td>All patients, <italic>n</italic>
</td><td char="." align="char">120</td><td char="." align="char">383</td><td char="." align="char">495</td><td char="." align="char">526</td></tr><tr><td>Total deaths</td><td char="." align="char">4</td><td char="." align="char">23</td><td char="." align="char">38</td><td char="." align="char">87</td></tr><tr><td>Progression to AP, BC</td><td char="." align="char">1</td><td char="." align="char">7</td><td char="." align="char">13</td><td char="." align="char">22</td></tr><tr><td>SCT related</td><td char="." align="char">2</td><td char="." align="char">6</td><td char="." align="char">8</td><td char="." align="char">1</td></tr><tr><td>Infection in CP</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="." align="char">8</td></tr><tr><td>Secondary malignancy</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">21</td></tr><tr><td>Bleeding</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">1</td><td char="." align="char">0</td></tr><tr><td>Cardiopulmonary</td><td char="." align="char">1</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">14</td></tr><tr><td>Renal insufficiency</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">3</td></tr><tr><td>Thromboembolic/ischemic (not cardiac)</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">2</td></tr><tr><td>Suicide</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">2</td></tr><tr><td>Others</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">4</td></tr><tr><td>Unknown</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">6</td><td char="." align="char">10</td></tr></tbody></table><table-wrap-foot><p>Multiple causes are possible. Autopsy performed only in few cases</p><p>
<italic>n</italic>&#x02009;number of patients, <italic>AP</italic>&#x02009;accelerated phase, <italic>BC</italic> blast crisis, <italic>CP</italic> chronic phase, <italic>SCT</italic> stem cell transplantation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>The median age of the 1,524 CML patients of the CML study IV was 52&#x000a0;years with a male preponderance. AYAs represented 8&#x000a0;% of the study population in agreement with reports of CML incidence in AYAs [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p>AYAs in our study presented features of a more aggressive disease, with higher levels of WBC and blasts in the peripheral blood, lower hemoglobin, larger spleen size, and more frequent organomegaly-related symptoms. The larger spleen size is reflected in the EUTOS score in which age is not included as a parameter and is in line with a study of Pemmaraju et al. who report a higher frequency of splenomegaly at diagnosis in 61 AYAs than in 407 older patients [<xref ref-type="bibr" rid="CR9">9</xref>], and a study of Cortes et al. who report that splenomegaly was more frequent in patients below 60&#x000a0;years than above 60&#x000a0;years [<xref ref-type="bibr" rid="CR6">6</xref>]. Similar observations have been made in children with CML (increased rates of splenomegaly and leucocytosis) [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>], supporting our findings that aggressive disease features become less apparent as age increases.</p><p>Although a worse outcome was expected in our group of 120 AYAs [<xref ref-type="bibr" rid="CR9">9</xref>], no differences in cumulative incidence of CCR, MMR, and MR<sup>4</sup> were observed in comparison to the other three groups. This is different from the results of Pemmaraju et al. [<xref ref-type="bibr" rid="CR9">9</xref>] who report significantly lower cytogenetic and molecular responses in AYAs. The two studies however did not find difference in OS. No inferior survival after a median observation time of 5.6&#x000a0;years was observed in our study either. We have observed, however, a greater percentage of younger patients with BCR-ABL transcript levels above 10&#x000a0;% at 3&#x000a0;months in comparison to patients 44&#x000a0;years and older. Transcript levels above 10&#x000a0;% are correlated with an unfavorable prognosis [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>] and identify patients that require more frequent monitoring [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p>These findings could suggest different disease biology of CML in younger patients. The identification of distinct age-related genetic and biologic features has been found in various neoplasms: in colon cancer chromosomal instability and a greater tumor invasion is observed in younger patients [<xref ref-type="bibr" rid="CR42">42</xref>]. In papillary thyroid cancer, different gene expression and advanced disease presentation in AYAs were correlated with better prognosis [<xref ref-type="bibr" rid="CR43">43</xref>]. In breast cancer, younger women show unique genetic pathways recognized as negative prognostic markers [<xref ref-type="bibr" rid="CR13">13</xref>]. In acute lymphoblastic leukemia (ALL), distinct biological findings are reported in AYAs, which are generally correlated with poor prognosis: increased incidence of Philadelphia chromosome and intrachromosomal amplification of chromosome 21, increased promoter methylation, and more frequent T cell immunophenotype as well as presence of a mediastinal mass. Due to treatment optimization, ALL outcome is better in AYAs than in adults [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p>In our analysis, we did not detect obvious biological differences. We did not observe differences in transcript type or ACAs nor did others: no differences in transcript type in relation to age were found in 146 pediatric CML patients, including 30 AYAs [<xref ref-type="bibr" rid="CR36">36</xref>]. Differences in stem cell biology, bone marrow microenvironment, or signaling pathways could exist since many biologic pathways are triggered by BCR-ABL and are successfully inhibited by TKI therapy [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>] but data to support this in AYAs are still lacking.</p><p>Another possible interpretation of the more aggressive features at diagnosis of CML in AYAs could be that younger patients are less frequently transferred to the physician than older ones and only when symptoms are apparent as a consequence of better health and less frequent comorbidities than in older people. As there are no data to support this hypothesis, this remains speculative.</p><p>Since the introduction of imatinib, response rates have improved and progression of the disease rarely occurs [<xref ref-type="bibr" rid="CR48">48</xref>]. Treatment with imatinib explains the high 5-year OS of AYAs in our study (97&#x000a0;%) in comparison to a recently published population-based study in the Netherlands, which started in the pre-imatinib era (1989&#x02013;2009), in which the 5-year relative survival of AYAs with CML is reported to be 68&#x000a0;% in males and 76&#x000a0;% in females [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p>We conclude that AYAs with CML show features of a more aggressive disease indicating possible biological differences of younger patients that need to be investigated. Also, the higher transcript level at 3&#x000a0;months suggests a worse prognosis of AYAs. Nevertheless, younger patients do well in spite of poorer prognostic indicators.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec5"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="277_2013_1937_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 33&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><fn-group><fn><p>Data presented in part at the ELN Frontiers Meeting, November 9&#x02013;11, 2012, Istanbul, Turkey</p></fn><fn><p>The study is registered at NIH, ClinicalTrials.gov identifier: NCT00055874 (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">http://clinicaltrials.gov</ext-link>)</p></fn></fn-group><ack><p>The authors would like to thank Gabriele Bartsch, Uwe B&#x000f6;hm, Elke Matzat, Sabine Dean, Ute Kossak, Barbara M&#x000fc;ller, Regina Pleil-L&#x000f6;sch, Nicole Schomber, Andrea Poetsch, Inge Stalljann, and all CML trial participants (see supplemental <xref rid="MOESM1" ref-type="media">Appendix</xref> in the online article).</p><sec id="d30e2591"><title>Conflict of interest</title><p>The CML study IV is supported by the Deutsche Krebshilfe (no. 106642 and 109588), Novartis, N&#x000fc;rnberg, Germany, Kompetenznetz f&#x000fc;r Akute and Chronische Leuk&#x000e4;mien (BMBF 01GI0270), Jos&#x000e9;-Carreras Leuk&#x000e4;miestiftung (DJCLS H09/01f, H06/04v, H03/01, R05/23), and the European LeukemiaNet (LSHC-CT-2004-503216). The authors declare no conflicts of interest.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K, (Editors) SEER Cancer Statistics Review, 1975&#x02013;2009 (Vintage 2009 Populations).Bethesda, MD:National Cancer Institute;2012http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 10 March 2012</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjorkholm</surname><given-names>M</given-names></name><name><surname>Ohm</surname><given-names>L</given-names></name><name><surname>Eloranta</surname><given-names>S</given-names></name><name><surname>Derolf</surname><given-names>A</given-names></name><name><surname>Hultcrantz</surname><given-names>M</given-names></name><name><surname>Sjoberg</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Hoglund</surname><given-names>M</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Landgren</surname><given-names>O</given-names></name><name><surname>Kristinsson</surname><given-names>SY</given-names></name><name><surname>Dickman</surname><given-names>PW</given-names></name></person-group><article-title>Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>18</issue><fpage>2514</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.34.7146</pub-id><pub-id pub-id-type="pmid">21576640</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohrbacher</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>U</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Metzgeroth</surname><given-names>G</given-names></name><name><surname>Adam</surname><given-names>K</given-names></name><name><surname>Lahaye</surname><given-names>T</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MC</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Heimpel</surname><given-names>H</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name></person-group><article-title>Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany</article-title><source>Leuk</source><year>2009</year><volume>23</volume><issue>3</issue><fpage>602</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/leu.2008.245</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokal</surname><given-names>JE</given-names></name><name><surname>Cox</surname><given-names>EB</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Tura</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>GA</given-names></name><name><surname>Robertson</surname><given-names>JE</given-names></name><name><surname>Tso</surname><given-names>CY</given-names></name><name><surname>Braun</surname><given-names>TJ</given-names></name><name><surname>Clarkson</surname><given-names>BD</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Rozman</surname><given-names>C</given-names></name></person-group><article-title>Prognostic discrimination in "good-risk" chronic granulocytic leukemia</article-title><source>Blood</source><year>1984</year><volume>63</volume><issue>4</issue><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">6584184</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Allan</surname><given-names>NC</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Kluin-Nelemans</surname><given-names>JC</given-names></name><name><surname>Alimena</surname><given-names>G</given-names></name><name><surname>Steegmann</surname><given-names>JL</given-names></name><name><surname>Ansari</surname><given-names>H</given-names></name></person-group><article-title>A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><issue>11</issue><fpage>850</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1093/jnci/90.11.850</pub-id><pub-id pub-id-type="pmid">9625174</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name><name><surname>Giles</surname><given-names>F</given-names></name><name><surname>Rios</surname><given-names>MB</given-names></name><name><surname>Shan</surname><given-names>JQ</given-names></name><name><surname>Faderl</surname><given-names>S</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Ferrajoli</surname><given-names>A</given-names></name><name><surname>Wierda</surname><given-names>W</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name></person-group><article-title>Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia</article-title><source>Cancer</source><year>2003</year><volume>98</volume><issue>6</issue><fpage>1105</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1002/cncr.11629</pub-id><pub-id pub-id-type="pmid">12973833</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosti</surname><given-names>G</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Bassi</surname><given-names>S</given-names></name><name><surname>Castagnetti</surname><given-names>F</given-names></name><name><surname>Amabile</surname><given-names>M</given-names></name><name><surname>Cilloni</surname><given-names>D</given-names></name><name><surname>Poerio</surname><given-names>A</given-names></name><name><surname>Soverini</surname><given-names>S</given-names></name><name><surname>Palandri</surname><given-names>F</given-names></name><name><surname>Cambrin</surname><given-names>GR</given-names></name><name><surname>Iuliano</surname><given-names>F</given-names></name><name><surname>Alimena</surname><given-names>G</given-names></name><name><surname>Latagliata</surname><given-names>R</given-names></name><name><surname>Testoni</surname><given-names>N</given-names></name><name><surname>Pane</surname><given-names>F</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name></person-group><article-title>Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party</article-title><source>Haematol</source><year>2007</year><volume>92</volume><issue>1</issue><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.3324/haematol.10239</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gugliotta</surname><given-names>G</given-names></name><name><surname>Castagnetti</surname><given-names>F</given-names></name><name><surname>Palandri</surname><given-names>F</given-names></name><name><surname>Breccia</surname><given-names>M</given-names></name><name><surname>Intermesoli</surname><given-names>T</given-names></name><name><surname>Capucci</surname><given-names>A</given-names></name><name><surname>Martino</surname><given-names>B</given-names></name><name><surname>Pregno</surname><given-names>P</given-names></name><name><surname>Rupoli</surname><given-names>S</given-names></name><name><surname>Ferrero</surname><given-names>D</given-names></name><name><surname>Gherlinzoni</surname><given-names>F</given-names></name><name><surname>Montefusco</surname><given-names>E</given-names></name><name><surname>Bocchia</surname><given-names>M</given-names></name><name><surname>Tiribelli</surname><given-names>M</given-names></name><name><surname>Pierri</surname><given-names>I</given-names></name><name><surname>Grifoni</surname><given-names>F</given-names></name><name><surname>Marzocchi</surname><given-names>G</given-names></name><name><surname>Amabile</surname><given-names>M</given-names></name><name><surname>Testoni</surname><given-names>N</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Alimena</surname><given-names>G</given-names></name><name><surname>Pane</surname><given-names>F</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Rosti</surname><given-names>G</given-names></name></person-group><article-title>Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party</article-title><source>Blood</source><year>2011</year><volume>117</volume><issue>21</issue><fpage>5591</fpage><lpage>5599</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-12-324228</pub-id><pub-id pub-id-type="pmid">21450900</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pemmaraju</surname><given-names>N</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Jabbour</surname><given-names>E</given-names></name><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Wierda</surname><given-names>W</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name></person-group><article-title>Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy</article-title><source>Haematol Hematol J</source><year>2012</year><volume>97</volume><issue>7</issue><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.3324/haematol.2011.056721</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stock</surname><given-names>W</given-names></name></person-group><article-title>Adolescents and young adults with acute lymphoblastic leukemia</article-title><source>ASH Educ Program Book</source><year>2010</year><volume>2010</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Advani</surname><given-names>AS</given-names></name></person-group><article-title>Biology and treatment of acute lymphocytic leukemia in adolescents and young adults</article-title><source>ASCO Educ Book</source><year>2013</year><volume>2013</volume><fpage>285</fpage><lpage>289</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>CK</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Litton</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>M</given-names></name><name><surname>Bleyer</surname><given-names>A</given-names></name></person-group><article-title>Breast cancer before age 40&#x000a0;years</article-title><source>Semin Oncol</source><year>2009</year><volume>36</volume><issue>3</issue><fpage>237</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2009.03.001</pub-id><pub-id pub-id-type="pmid">19460581</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>CK</given-names></name><name><surname>Hsu</surname><given-names>DS</given-names></name><name><surname>Broadwater</surname><given-names>G</given-names></name><name><surname>Acharya</surname><given-names>CR</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Marcom</surname><given-names>PK</given-names></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Febbo</surname><given-names>PG</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name><name><surname>Potti</surname><given-names>A</given-names></name><name><surname>Blackwell</surname><given-names>KL</given-names></name></person-group><article-title>Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>20</issue><fpage>3324</fpage><lpage>3330</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.2471</pub-id><pub-id pub-id-type="pmid">18612148</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>RV</given-names></name><name><surname>LaQuaglia</surname><given-names>MP</given-names></name><name><surname>Paty</surname><given-names>PB</given-names></name></person-group><article-title>Genetic and phenotypic correlates of colorectal cancer in young patients</article-title><source>New Eng J Med</source><year>2000</year><volume>342</volume><issue>2</issue><fpage>137</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1056/NEJM200001133420216</pub-id><pub-id pub-id-type="pmid">10636759</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakash</surname><given-names>S</given-names></name><name><surname>Sarran</surname><given-names>L</given-names></name><name><surname>Socci</surname><given-names>N</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name><name><surname>Eisenstat</surname><given-names>J</given-names></name><name><surname>Greco</surname><given-names>AM</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Wexler</surname><given-names>LH</given-names></name><name><surname>LaQuaglia</surname><given-names>MP</given-names></name><name><surname>Besmer</surname><given-names>P</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name></person-group><article-title>Gastrointestinal stromal tumors in children and young adults&#x02014;a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature</article-title><source>J Pediatr Hematol Oncol</source><year>2005</year><volume>27</volume><issue>4</issue><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1097/01.mph.0000157790.81329.47</pub-id><pub-id pub-id-type="pmid">15838387</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleyer</surname><given-names>A</given-names></name><name><surname>Barr</surname><given-names>R</given-names></name><name><surname>Hayes-Lattin</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Ellis</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>B</given-names></name></person-group><article-title>The distinctive biology of cancer in adolescents and young adults</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><issue>4</issue><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/nrc2349</pub-id><pub-id pub-id-type="pmid">18354417</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Jung-Munkwitz</surname><given-names>S</given-names></name><name><surname>Leitner</surname><given-names>A</given-names></name><name><surname>Mueller</surname><given-names>MC</given-names></name><name><surname>Pletsch</surname><given-names>N</given-names></name><name><surname>Proetel</surname><given-names>U</given-names></name><name><surname>Haferlach</surname><given-names>C</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><name><surname>Balleisen</surname><given-names>L</given-names></name><name><surname>Haenel</surname><given-names>M</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Krause</surname><given-names>SW</given-names></name><name><surname>Nerl</surname><given-names>C</given-names></name><name><surname>Pralle</surname><given-names>H</given-names></name><name><surname>Gratwohl</surname><given-names>A</given-names></name><name><surname>Hossfeld</surname><given-names>DK</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name></person-group><article-title>Tolerability-adapted imatinib 800&#x000a0;mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>12</issue><fpage>1634</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.32.0598</pub-id><pub-id pub-id-type="pmid">21422420</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleyer</surname><given-names>WA</given-names></name></person-group><article-title>Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials</article-title><source>Med Pediatr Oncol</source><year>2002</year><volume>38</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/mpo.1257</pub-id><pub-id pub-id-type="pmid">11835231</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wein</surname><given-names>S</given-names></name><name><surname>Pery</surname><given-names>S</given-names></name><name><surname>Zer</surname><given-names>A</given-names></name></person-group><article-title>Role of palliative care in adolescent and young adult oncology</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>32</issue><fpage>4819</fpage><lpage>4824</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.4543</pub-id><pub-id pub-id-type="pmid">20212259</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Franklin</surname><given-names>ARK</given-names></name><name><surname>Hayes-Lattin</surname><given-names>BM</given-names></name><name><surname>Mascarin</surname><given-names>M</given-names></name><name><surname>van der Graaf</surname><given-names>W</given-names></name><name><surname>Albritton</surname><given-names>KH</given-names></name></person-group><article-title>Starting an adolescent and young adult program: some success stories and some obstacles to overcome</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>32</issue><fpage>4850</fpage><lpage>4857</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.8097</pub-id><pub-id pub-id-type="pmid">20479411</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonorezos</surname><given-names>ES</given-names></name><name><surname>Oeffinger</surname><given-names>KC</given-names></name></person-group><article-title>Research challenges in adolescent and young adult cancer survivor research</article-title><source>Cancer</source><year>2011</year><volume>117</volume><issue>10</issue><fpage>2295</fpage><lpage>2300</lpage><pub-id pub-id-type="doi">10.1002/cncr.26058</pub-id><pub-id pub-id-type="pmid">21523749</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latagliata</surname><given-names>R</given-names></name><name><surname>Breccia</surname><given-names>M</given-names></name><name><surname>Carmosino</surname><given-names>I</given-names></name><etal/></person-group><article-title>Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment</article-title><source>Leukemia Research</source><year>2005</year><volume>29</volume><issue>3</issue><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2004.08.002</pub-id><pub-id pub-id-type="pmid">15661264</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabarius</surname><given-names>A</given-names></name><name><surname>Leitner</surname><given-names>A</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MC</given-names></name><name><surname>Hanfstein</surname><given-names>B</given-names></name><name><surname>Haferlach</surname><given-names>C</given-names></name><name><surname>Gohring</surname><given-names>G</given-names></name><name><surname>Schlegelberger</surname><given-names>B</given-names></name><name><surname>Jotterand</surname><given-names>M</given-names></name><name><surname>Reiter</surname><given-names>A</given-names></name><name><surname>Jung-Munkwitz</surname><given-names>S</given-names></name><name><surname>Proetel</surname><given-names>U</given-names></name><name><surname>Schwaab</surname><given-names>J</given-names></name><name><surname>Hofmann</surname><given-names>WK</given-names></name><name><surname>Schubert</surname><given-names>J</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Ho</surname><given-names>AD</given-names></name><name><surname>Falge</surname><given-names>C</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Kneba</surname><given-names>M</given-names></name><name><surname>Stegelmann</surname><given-names>F</given-names></name><name><surname>Pfreundschuh</surname><given-names>M</given-names></name><name><surname>Waller</surname><given-names>CF</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Baerlocher</surname><given-names>GM</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name></person-group><article-title>Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV</article-title><source>Blood</source><year>2011</year><volume>118</volume><issue>26</issue><fpage>6760</fpage><lpage>6768</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-08-373902</pub-id><pub-id pub-id-type="pmid">22039253</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Radich</surname><given-names>J</given-names></name><name><surname>Kaeda</surname><given-names>J</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Cross</surname><given-names>NC</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Gabert</surname><given-names>J</given-names></name><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Kamel-Reid</surname><given-names>S</given-names></name><name><surname>Lipton</surname><given-names>JH</given-names></name><name><surname>Longtine</surname><given-names>J</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Soverini</surname><given-names>S</given-names></name><name><surname>Stock</surname><given-names>W</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name></person-group><article-title>Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results</article-title><source>Blood</source><year>2006</year><volume>108</volume><issue>1</issue><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-01-0092</pub-id><pub-id pub-id-type="pmid">16522812</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emig</surname><given-names>M</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Wittor</surname><given-names>H</given-names></name><name><surname>Weisser</surname><given-names>A</given-names></name><name><surname>Reiter</surname><given-names>A</given-names></name><name><surname>Willer</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>U</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Cross</surname><given-names>NCP</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name></person-group><article-title>Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR</article-title><source>Leuk</source><year>1999</year><volume>13</volume><issue>11</issue><fpage>1825</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401566</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>NC</given-names></name></person-group><article-title>Standardisation of molecular monitoring for chronic myeloid leukaemia</article-title><source>Best Pract Res Clin Haematol</source><year>2009</year><volume>22</volume><issue>3</issue><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.beha.2009.04.001</pub-id><pub-id pub-id-type="pmid">19959086</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>MC</given-names></name><name><surname>Cross</surname><given-names>NCP</given-names></name><name><surname>Erben</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>T</given-names></name><name><surname>Hanfstein</surname><given-names>B</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name></person-group><article-title>Harmonization of molecular monitoring of CML therapy in Europe</article-title><source>Leuk</source><year>2009</year><volume>23</volume><issue>11</issue><fpage>1957</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.1038/leu.2009.168</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Pane</surname><given-names>F</given-names></name><name><surname>Niederwieser</surname><given-names>D</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Gratwohl</surname><given-names>A</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Larson</surname><given-names>R</given-names></name><name><surname>Radich</surname><given-names>J</given-names></name><name><surname>Simonsson</surname><given-names>B</given-names></name><name><surname>Silver</surname><given-names>RT</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name></person-group><article-title>Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>35</issue><fpage>6041</fpage><lpage>6051</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.0779</pub-id><pub-id pub-id-type="pmid">19884523</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>NCP</given-names></name><name><surname>White</surname><given-names>HE</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MC</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name></person-group><article-title>Standardized definitions of molecular response in chronic myeloid leukemia</article-title><source>Leuk</source><year>2012</year><volume>26</volume><issue>10</issue><fpage>2172</fpage><lpage>2175</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.104</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Simonsson</surname><given-names>B</given-names></name><name><surname>Appelbaum</surname><given-names>F</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Gratwohl</surname><given-names>A</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Larson</surname><given-names>R</given-names></name><name><surname>Niederwieser</surname><given-names>D</given-names></name><name><surname>Silver</surname><given-names>R</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name></person-group><article-title>Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet</article-title><source>Blood</source><year>2006</year><volume>108</volume><issue>6</issue><fpage>1809</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-02-005686</pub-id><pub-id pub-id-type="pmid">16709930</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Sausele</surname><given-names>S</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name></person-group><article-title>Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia</article-title><source>Leukemia</source><year>2011</year><volume>25</volume><issue>9</issue><fpage>1433</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1038/leu.2011.116</pub-id><pub-id pub-id-type="pmid">21597465</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooley</surname><given-names>T</given-names></name><name><surname>Leisenring</surname><given-names>W</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name><name><surname>Storer</surname><given-names>BE</given-names></name></person-group><article-title>Estimation of failure probabilities in the presence of competiting risks:new representations of old estimators</article-title><source>Stat Med</source><year>1999</year><volume>18</volume><issue>6</issue><fpage>695</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19990330)18:6&#x0003c;695::AID-SIM60&#x0003e;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">10204198</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A class of k-sample tests for comparing the cumulative incidence of a competing risk</article-title><source>Ann Stat</source><year>1988</year><volume>16</volume><issue>3</issue><fpage>1141</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1214/aos/1176350951</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Statistical Yearbook for the Federal Republic of Germany including "International tables" (2011). Federal Statistical Office, Wiesbaden</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Bleyer A OLM, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival:1975&#x02013;2000. National Cancer Institute, NIH Pub. No. 06&#x02013;5767. Bethesda, MD 2006. <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/publications/aya/">http://seer.cancer.gov/publications/aya/</ext-link>. Accessed 10 March 2012.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>R</given-names></name><name><surname>Viehmann</surname><given-names>S</given-names></name><name><surname>Kuhlisch</surname><given-names>E</given-names></name><name><surname>Martiniak</surname><given-names>Y</given-names></name><name><surname>R&#x000f6;ttgers</surname><given-names>S</given-names></name><name><surname>Harbott</surname><given-names>J</given-names></name><name><surname>Suttorp</surname><given-names>M</given-names></name></person-group><article-title>Correlation of BCR/ABL transcript variants with patients characteristics in childhood chronic myeloid leukemia</article-title><source>Eur J Haematol</source><year>2009</year><volume>82</volume><issue>2</issue><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2008.01170.x</pub-id><pub-id pub-id-type="pmid">19067742</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millot</surname><given-names>F</given-names></name><name><surname>Suttorp</surname><given-names>M</given-names></name><name><surname>Guilhot</surname><given-names>J</given-names></name><name><surname>Sedlacek</surname><given-names>P</given-names></name><name><surname>De Bont</surname><given-names>ES</given-names></name><name><surname>Li</surname><given-names>CK</given-names></name><name><surname>Kalwak</surname><given-names>K</given-names></name><name><surname>Lausen</surname><given-names>B</given-names></name><name><surname>Srdjana</surname><given-names>C</given-names></name><name><surname>Dresse</surname><given-names>M-F</given-names></name><name><surname>Biondi</surname><given-names>A</given-names></name><name><surname>Baruchel</surname><given-names>A</given-names></name></person-group><article-title>The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): objectives and preliminary results</article-title><source>ASH Annu Meeting Abstracts</source><year>2012</year><volume>120</volume><issue>21</issue><fpage>3741</fpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millot</surname><given-names>F</given-names></name><name><surname>Traore</surname><given-names>P</given-names></name><name><surname>Guilhot</surname><given-names>J</given-names></name><name><surname>Nelken</surname><given-names>B</given-names></name><name><surname>Leblanc</surname><given-names>T</given-names></name><name><surname>Leverger</surname><given-names>G</given-names></name><name><surname>Plantaz</surname><given-names>D</given-names></name><name><surname>Bertrand</surname><given-names>Y</given-names></name><name><surname>Bordigoni</surname><given-names>P</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name></person-group><article-title>Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia</article-title><source>Pediatr</source><year>2005</year><volume>116</volume><issue>1</issue><fpage>140</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1542/peds.2004-2473</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanfstein</surname><given-names>B</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MC</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name><name><surname>Erben</surname><given-names>P</given-names></name><name><surname>Lauseker</surname><given-names>M</given-names></name><name><surname>Fabarius</surname><given-names>A</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Haferlach</surname><given-names>C</given-names></name><name><surname>Goehring</surname><given-names>G</given-names></name><name><surname>Proetel</surname><given-names>U</given-names></name><name><surname>Kolb</surname><given-names>HJ</given-names></name><name><surname>Krause</surname><given-names>SW</given-names></name><name><surname>Hofmann</surname><given-names>WK</given-names></name><name><surname>Schubert</surname><given-names>J</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Dengler</surname><given-names>J</given-names></name><name><surname>Haenel</surname><given-names>M</given-names></name><name><surname>Falge</surname><given-names>C</given-names></name><name><surname>Kanz</surname><given-names>L</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Kneba</surname><given-names>M</given-names></name><name><surname>Stegelmann</surname><given-names>F</given-names></name><name><surname>Pfreundschuh</surname><given-names>M</given-names></name><name><surname>Waller</surname><given-names>CF</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Baerlocher</surname><given-names>GM</given-names></name><name><surname>Pfirrmann</surname><given-names>M</given-names></name><name><surname>Hasford</surname><given-names>J</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Sakk</surname><given-names>GCMLSG</given-names></name></person-group><article-title>Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)</article-title><source>Leuk</source><year>2012</year><volume>26</volume><issue>9</issue><fpage>2096</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1038/leu.2012.85</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>D</given-names></name><name><surname>Ibrahim</surname><given-names>AR</given-names></name><name><surname>Lucas</surname><given-names>C</given-names></name><name><surname>Gerrard</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Szydlo</surname><given-names>RM</given-names></name><name><surname>Clark</surname><given-names>RE</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Milojkovic</surname><given-names>D</given-names></name><name><surname>Bua</surname><given-names>M</given-names></name><name><surname>Pavlu</surname><given-names>J</given-names></name><name><surname>Paliompeis</surname><given-names>C</given-names></name><name><surname>Reid</surname><given-names>A</given-names></name><name><surname>Rezvani</surname><given-names>K</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>Foroni</surname><given-names>L</given-names></name></person-group><article-title>Assessment of BCR-ABL1 transcript levels at 3&#x000a0;months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>3</issue><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.38.6565</pub-id><pub-id pub-id-type="pmid">22067393</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Rosti</surname><given-names>G</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Soverini</surname><given-names>S</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Clark</surname><given-names>RE</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Hjorth-Hansen</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Larson</surname><given-names>RA</given-names></name><name><surname>Lipton</surname><given-names>JH</given-names></name><name><surname>Mahon</surname><given-names>FX</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>MC</given-names></name><name><surname>Niederwieser</surname><given-names>D</given-names></name><name><surname>Pane</surname><given-names>F</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Schiffer</surname><given-names>C</given-names></name><name><surname>Silver</surname><given-names>R</given-names></name><name><surname>Simonsson</surname><given-names>B</given-names></name><name><surname>Steegmann</surname><given-names>JL</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>Hehlmann</surname><given-names>R</given-names></name></person-group><article-title>European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013</article-title><source>Blood</source><year>2013</year></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryfe</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hsieh</surname><given-names>ETK</given-names></name><name><surname>Aronson</surname><given-names>MD</given-names></name><name><surname>Holowaty</surname><given-names>EJ</given-names></name><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Redston</surname><given-names>M</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name></person-group><article-title>Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>2</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1056/NEJM200001133420201</pub-id><pub-id pub-id-type="pmid">10631274</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vriens</surname><given-names>M</given-names></name><name><surname>Moses</surname><given-names>W</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical and molecular features of papillary thyroid cancer in adolescents and young adults</article-title><source>Cancer</source><year>2011</year><volume>117</volume><issue>2</issue><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1002/cncr.25369</pub-id><pub-id pub-id-type="pmid">20824721</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>CJ</given-names></name></person-group><article-title>Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia</article-title><source>Br J Haematol</source><year>2009</year><volume>144</volume><issue>2</issue><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07417.x</pub-id><pub-id pub-id-type="pmid">19006567</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belloc</surname><given-names>F</given-names></name><name><surname>Moreau-Gaudry</surname><given-names>F</given-names></name><name><surname>Uhalde</surname><given-names>M</given-names></name><name><surname>Cazalis</surname><given-names>L</given-names></name><name><surname>Jeanneteau</surname><given-names>M</given-names></name><name><surname>Lacombe</surname><given-names>F</given-names></name><name><surname>Praloran</surname><given-names>V</given-names></name><name><surname>Mahon</surname><given-names>F-X</given-names></name></person-group><article-title>Imatinib and Nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines</article-title><source>Cancer Biology &#x00026; Therapy</source><year>2007</year><volume>6</volume><issue>6</issue><fpage>912</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.4161/cbt.6.6.4101</pub-id><pub-id pub-id-type="pmid">17538248</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>T</given-names></name><name><surname>Holyoake</surname><given-names>TL</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name><name><surname>Shultz</surname><given-names>L</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name></person-group><article-title>Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt&#x02013;&#x003b2;-catenin signaling</article-title><source>Blood</source><year>2013</year><volume>121</volume><issue>10</issue><fpage>1824</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-02-412890</pub-id><pub-id pub-id-type="pmid">23299311</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustjoki</surname><given-names>S</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Barbany</surname><given-names>G</given-names></name><name><surname>Ehrencrona</surname><given-names>H</given-names></name><name><surname>Fioretos</surname><given-names>T</given-names></name><name><surname>Gedde-Dahl</surname><given-names>T</given-names></name><name><surname>Gjertsen</surname><given-names>BT</given-names></name><name><surname>Hovland</surname><given-names>R</given-names></name><name><surname>Hernesniemi</surname><given-names>S</given-names></name><name><surname>Josefsen</surname><given-names>D</given-names></name><name><surname>Koskenvesa</surname><given-names>P</given-names></name><name><surname>Dybedal</surname><given-names>I</given-names></name><name><surname>Markevarn</surname><given-names>B</given-names></name><name><surname>Olofsson</surname><given-names>T</given-names></name><name><surname>Olsson-Stromberg</surname><given-names>U</given-names></name><name><surname>Rapakko</surname><given-names>K</given-names></name><name><surname>Thunberg</surname><given-names>S</given-names></name><name><surname>Stenke</surname><given-names>L</given-names></name><name><surname>Simonsson</surname><given-names>B</given-names></name><name><surname>Porkka</surname><given-names>K</given-names></name><name><surname>Hjorth-Hansen</surname><given-names>H</given-names></name></person-group><article-title>Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients</article-title><source>Leuk</source><year>2013</year><volume>27</volume><issue>7</issue><fpage>1520</fpage><lpage>1526</lpage></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>SG</given-names></name><name><surname>Gathmann</surname><given-names>I</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Silver</surname><given-names>RT</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Powell</surname><given-names>BL</given-names></name><name><surname>Gabrilove</surname><given-names>JL</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Reiffers</surname><given-names>J</given-names></name><name><surname>Cornelissen</surname><given-names>JJ</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Agis</surname><given-names>H</given-names></name><name><surname>Fischer</surname><given-names>T</given-names></name><name><surname>Verhoef</surname><given-names>G</given-names></name><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Saglio</surname><given-names>G</given-names></name><name><surname>Gratwohl</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>JL</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Simonsson</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>So</surname><given-names>C</given-names></name><name><surname>Letvak</surname><given-names>L</given-names></name><name><surname>Larson</surname><given-names>RA</given-names></name></person-group><article-title>Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>23</issue><fpage>2408</fpage><lpage>2417</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa062867</pub-id><pub-id pub-id-type="pmid">17151364</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aben</surname><given-names>KKVGC</given-names></name><name><surname>Van Gils</surname><given-names>NA</given-names></name><name><surname>Van der Graaf</surname><given-names>WT</given-names></name><name><surname>Zielhuis</surname><given-names>GA</given-names></name></person-group><article-title>Cancer in adolescents and young adults (15&#x02013;29 years): a population-based study in the Netherlands 1989&#x02013;2009</article-title><source>Acta Oncologica</source><year>2012</year><volume>51</volume><issue>7</issue><fpage>922</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.3109/0284186X.2012.705891</pub-id><pub-id pub-id-type="pmid">22934554</pub-id></element-citation></ref></ref-list></back></article>